TY - JOUR
T1 - Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders
AU - Aoki, Yoshiyasu
AU - Yarchoan, Robert
AU - Wyvill, Kathleen
AU - Okamoto, Shin Ichiro
AU - Little, Richard F.
AU - Tosato, Giovanna
N1 - Funding Information:
The authors thank Jan-Erik Holm, Lisbet Benthin, and Lars Gothe for their excellent technical assistance; and Dr. Olof Nylander, Biomedical Center, Uppsala University, for valuable comments on the oxygen levels as they pertain to the intestines. Grants from the Swedish Medical Research Council (project No. 24X-13450) and from the Karolinska Institute are gratefully ac know Ie dged. Submitted for publication August 14, 2003; revised; accepted for publication August 10, 2004. Requests for reprints should be sent to Dr. Gunilla Sandborgh-Englund, Institute of Odontology, Karolinska Institutet, Karolinska University Hospital, PO Box 4064, SE-141 04 Huddinge, Sweden. E-mai I : Gun il la.Sand borghaki .se Copyright 0 2005 Heldref Publications
PY - 2001/4/1
Y1 - 2001/4/1
N2 - Expression of a viral interleukin-6 (vIL-6) has been detected in certain Kaposi sarcoma (KS)-associated herpesvirus positive (KSHV+) lesions. The release of vIL-6 systemically and its contribution to the pathogenesis of HIV-related malignancies was studied. Serum vIL-6 was detected in 13 (38.2%) of 34 HIV+ patients with KS, in 6 (85.7%) of 7 HIV+ patients with primary effusion lymphoma (PEL) and/or multicentric Castleman disease (MCD), and in 18 (60.0%) of 30 HIV+, mostly homosexual, individuals without KS, MCD, or PEL. By contrast, serum vIL-6 was detected in only 3 (23.1%) of 13 patients with classic KS, 1 (2.5%) of 40 blood donors from the United States, and 4 (19.0%) of 21 blood donors from Italy. Circulating vIL-6 levels were associated with HIV+ status (P<.0001). However, within the HIV+ cohort, serum vIL-6 levels were not associated with the occurrence of KSHV-associated malignancies (P = .43).
AB - Expression of a viral interleukin-6 (vIL-6) has been detected in certain Kaposi sarcoma (KS)-associated herpesvirus positive (KSHV+) lesions. The release of vIL-6 systemically and its contribution to the pathogenesis of HIV-related malignancies was studied. Serum vIL-6 was detected in 13 (38.2%) of 34 HIV+ patients with KS, in 6 (85.7%) of 7 HIV+ patients with primary effusion lymphoma (PEL) and/or multicentric Castleman disease (MCD), and in 18 (60.0%) of 30 HIV+, mostly homosexual, individuals without KS, MCD, or PEL. By contrast, serum vIL-6 was detected in only 3 (23.1%) of 13 patients with classic KS, 1 (2.5%) of 40 blood donors from the United States, and 4 (19.0%) of 21 blood donors from Italy. Circulating vIL-6 levels were associated with HIV+ status (P<.0001). However, within the HIV+ cohort, serum vIL-6 levels were not associated with the occurrence of KSHV-associated malignancies (P = .43).
UR - https://www.scopus.com/pages/publications/0035312975
UR - https://www.scopus.com/pages/publications/0035312975#tab=citedBy
U2 - 10.1182/blood.V97.7.2173
DO - 10.1182/blood.V97.7.2173
M3 - Article
C2 - 11264189
AN - SCOPUS:0035312975
SN - 0006-4971
VL - 97
SP - 2173
EP - 2176
JO - Blood
JF - Blood
IS - 7
ER -
SDG 3 すべての人に健康と福祉を